In preclinical models, increasing autophagy via pharmacological or genetic treatments has demonstrated promise by encouraging the removal of tau and Aβ, making it a possible therapeutic target for slowing the course of AD [34]. The gene discussed is MAPT; the disease is Alzheimer disease.